383 related articles for article (PubMed ID: 35364753)
21. An Updated Comprehensive Pharmacovigilance Study of Drug-Induced Thrombocytopenia Based on FDA Adverse Event Reporting System Data.
Kunyu L; Shuping S; Chang S; Yiyue C; Qinyu X; Ting Z; Bin W
J Clin Pharmacol; 2024 Apr; 64(4):478-489. PubMed ID: 38041205
[TBL] [Abstract][Full Text] [Related]
22. Liver injury with drugs used for multiple sclerosis: A contemporary analysis of the FDA Adverse Event Reporting System.
Antonazzo IC; Poluzzi E; Forcesi E; Riise T; Bjornevik K; Baldin E; Muratori L; De Ponti F; Raschi E
Mult Scler; 2019 Oct; 25(12):1633-1640. PubMed ID: 30230957
[TBL] [Abstract][Full Text] [Related]
23. Hepatotoxicity reports in the FDA adverse event reporting system database: A comparison of drugs that cause injury
Rana P; Aleo MD; Wen X; Kogut S
Acta Pharm Sin B; 2021 Dec; 11(12):3857-3868. PubMed ID: 35024312
[TBL] [Abstract][Full Text] [Related]
24. Fluid retention-associated adverse events in patients treated with BCR::ABL1 inhibitors based on FDA Adverse Event Reporting System (FAERS): a retrospective pharmacovigilance study.
Huang J; Cai J; Ye Q; Jiang Q; Lin H; Wu L
BMJ Open; 2023 Aug; 13(8):e071456. PubMed ID: 37536976
[TBL] [Abstract][Full Text] [Related]
25. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
26. Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA Adverse Event Reporting System (FAERS) database.
Brinker AD; Lyndly J; Tonning J; Moeny D; Levine JG; Avigan MI
Drug Saf; 2013 Dec; 36(12):1169-78. PubMed ID: 24178291
[TBL] [Abstract][Full Text] [Related]
27. A pharmacovigilance study on drug-induced liver injury associated with antibody-drug conjugates (ADCs) based on the food and drug administration adverse event reporting system.
Sun C; Yang X; Tang L; Chen J
Expert Opin Drug Saf; 2023 Oct; ():1-12. PubMed ID: 37898875
[TBL] [Abstract][Full Text] [Related]
28. Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
Subeesh V; Maheswari E; Singh H; Beulah TE; Swaroop AM
Curr Drug Saf; 2019; 14(1):21-26. PubMed ID: 30362421
[TBL] [Abstract][Full Text] [Related]
29. A pharmacovigilance analysis of FDA adverse event reporting system events for romosozumab.
Chen Z; Li M; Li S; Li Y; Wu J; Qiu K; Yu X; Huang L; Chen G
Expert Opin Drug Saf; 2023 Apr; 22(4):339-342. PubMed ID: 36178002
[TBL] [Abstract][Full Text] [Related]
30. Inverse association between DPP-4 inhibitor use and fracture in older adults: A disproportionality analysis of the FAERS and JADER.
Ohyama K; Okamoto T; Hori Y
Int J Clin Pharmacol Ther; 2023 Jan; 61(1):16-23. PubMed ID: 36366967
[TBL] [Abstract][Full Text] [Related]
31. Data mining and analysis of adverse event signals associated with teprotumumab using the Food and Drug Administration adverse event reporting system database.
Zhang S; Wang Y; Qi Z; Tong S; Zhu D
Int J Clin Pharm; 2024 Apr; 46(2):471-479. PubMed ID: 38245664
[TBL] [Abstract][Full Text] [Related]
32. Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System.
Zhao D; Long X; Zhou J; Wang J
Drugs R D; 2023 Dec; 23(4):403-409. PubMed ID: 37700091
[TBL] [Abstract][Full Text] [Related]
33. Acute renal failure and cardiac arrhythmias associated with remdesivir use in patients with COVID-19 infections: Analysis using the US FDA adverse event reporting system.
Orogun L; Chyou TY; Nishtala PS
Int J Risk Saf Med; 2023; 34(2):87-99. PubMed ID: 37154187
[TBL] [Abstract][Full Text] [Related]
34. Drug-induced liver injury associated with lopinavir-ritonavir in patients with COVID-19: a disproportionality analysis of U.S. food and drug administration adverse event reporting system (FAERS) data.
Tang H; Zhou L; Li X; Kinlaw AC; Yang JY; Moon AM; Barnes EL; Wang T
Int J Clin Pharm; 2021 Aug; 43(4):1116-1122. PubMed ID: 34328585
[TBL] [Abstract][Full Text] [Related]
35. Adverse event profile of tigecycline: data mining of the public version of the U.S. Food and Drug Administration adverse event reporting system.
Kadoyama K; Sakaeda T; Tamon A; Okuno Y
Biol Pharm Bull; 2012; 35(6):967-70. PubMed ID: 22687540
[TBL] [Abstract][Full Text] [Related]
36. Ocular disorders associated with PCSK9 inhibitors: A pharmacovigilance disproportionality analysis.
Zhao X; Wu J; Zhu S
Br J Clin Pharmacol; 2023 Feb; 89(2):458-469. PubMed ID: 35973681
[TBL] [Abstract][Full Text] [Related]
37. Minocycline hepatotoxicity: Clinical characterization and identification of HLA-B∗35:02 as a risk factor.
Urban TJ; Nicoletti P; Chalasani N; Serrano J; Stolz A; Daly AK; Aithal GP; Dillon J; Navarro V; Odin J; Barnhart H; Ostrov D; Long N; Cirulli ET; Watkins PB; Fontana RJ; ; ;
J Hepatol; 2017 Jul; 67(1):137-144. PubMed ID: 28323125
[TBL] [Abstract][Full Text] [Related]
38. DPP-4 Inhibitors and Increased Reporting Odds of Bullous Pemphigoid: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 2020.
Jedlowski PM; Jedlowski MF; Fazel MT
Am J Clin Dermatol; 2021 Nov; 22(6):891-900. PubMed ID: 34287770
[TBL] [Abstract][Full Text] [Related]
39. A real-world pharmacovigilance study of severe cutaneous adverse reactions associated with antiepileptic drug combination therapy: data mining of FDA adverse event reporting system.
Wei C; Zhang J; Yin W; Jiang A; Liu Y; Wu B
Expert Opin Drug Saf; 2023; 22(6):509-515. PubMed ID: 36373417
[TBL] [Abstract][Full Text] [Related]
40. Safety profile of D-penicillamine: a comprehensive pharmacovigilance analysis by FDA adverse event reporting system.
Kumar V; Singh AP; Wheeler N; Galindo CL; Kim JJ
Expert Opin Drug Saf; 2021 Nov; 20(11):1443-1450. PubMed ID: 34259127
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
